Recently, genome-wide CRISPR/Cas9 screening led to the identification of p53 and BAX as key factors of resistance [52], and it is of interest that 17% of AML patients relapsing after VEN-based therapy have acquired inactivating missense or frameshift/nonsense mutations of BAX [51]. The gene discussed is BAX; the disease is acute myeloid leukemia.